Clinical Trials
27 trialsA Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
National Cancer Institute (NCI)
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
St. Jude Children's Research Hospital
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
National Cancer Institute (NCI)
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Hoosier Cancer Research Network
STOMP
Karyopharm Therapeutics Inc
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
Mayo Clinic
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
University of California, Davis
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
National University Hospital, Singapore
SWATCH
Antengene Corporation
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
Institute of Hematology & Blood Diseases Hospital, China
SPRINT
Karyopharm Therapeutics Inc
MyDRUG
Multiple Myeloma Research Consortium
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma
Sun Yat-sen University
Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
University of Texas Southwestern Medical Center
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
SLAM
Karyopharm Therapeutics Inc
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Selinexor Combination Ph 1 Study
Hackensack Meridian Health
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
Sichuan University
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
Washington University School of Medicine
Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer
Ohio State University Comprehensive Cancer Center